Sherpa opens new CGMP production facility in San Diego
The new facility houses five controlled access and monitored packaging suites, and walk-in 2-8 degrees C and -20 degrees C storage areas. The company has also installed alarms,
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.
The new approved vaccine formulation targets A/California/7/09 (H1N1)-like virus (pandemic (H1N1) 2009 influenza virus), A/Perth /16/2009 (H3N2)-like virus and B/Brisbane/60/2008-like virus strains. CSL, GlaxoSmithKline Biologicals, ID Biomedical, MedImmune